Advanced search
1 file | 1.73 MB Add to list

Development of the nanobody display technology to target lentiviral vectors to antigen-presenting cells

(2012) GENE THERAPY. 19(12). p.1133-1140
Author
Organization
Abstract
Lentiviral vectors (LVs) provide unique opportunities for the development of immunotherapeutic strategies, as they transduce a variety of cells in situ, including antigen-presenting cells (APCs). Engineering LVs to specifically transduce APCs is required to promote their translation towards the clinic. We report on the Nanobody (Nb) display technology to target LVs to dendritic cells (DCs) and macrophages. This innovative approach exploits the budding mechanism of LVs to incorporate an APC-specific Nb and a binding-defective, fusion-competent form of VSV. G in the viral envelope. In addition to production of high titer LVs, we demonstrated selective, Nb-dependent transduction of mouse DCs and macrophages both in vitro and in situ. Moreover, this strategy was translated to a human model in which selective transduction of in vitro generated or lymph node (LN)-derived DCs and macrophages, was demonstrated. In conclusion, the Nb display technology is an attractive approach to generate LVs targeted to specific cell types.
Keywords
CANCER-IMMUNOTHERAPY, GENETIC-MODIFICATION, IN-VIVO, DENDRITIC CELLS, VESICULAR STOMATITIS-VIRUS, targeting, lentiviral vector, antigen-presenting cell, Nanobody, T-CELLS, TRANSDUCTION, IMMUNIZATION, IMMUNITY, THERAPY

Downloads

  • Goyvaerts 2012 GT 19 12 1133.pdf
    • full text
    • |
    • open access
    • |
    • PDF
    • |
    • 1.73 MB

Citation

Please use this url to cite or link to this publication:

MLA
Goyvaerts, Cleo, Kurt De Groeve, Jozef Dingemans, et al. “Development of the Nanobody Display Technology to Target Lentiviral Vectors to Antigen-presenting Cells.” GENE THERAPY 19.12 (2012): 1133–1140. Print.
APA
Goyvaerts, C., De Groeve, K., Dingemans, J., Van Lint, S., Robays, L., Heirman, C., Reiser, J., et al. (2012). Development of the nanobody display technology to target lentiviral vectors to antigen-presenting cells. GENE THERAPY, 19(12), 1133–1140.
Chicago author-date
Goyvaerts, Cleo, Kurt De Groeve, Jozef Dingemans, Sandra Van Lint, Lander Robays, Carlo Heirman, J Reiser, et al. 2012. “Development of the Nanobody Display Technology to Target Lentiviral Vectors to Antigen-presenting Cells.” Gene Therapy 19 (12): 1133–1140.
Chicago author-date (all authors)
Goyvaerts, Cleo, Kurt De Groeve, Jozef Dingemans, Sandra Van Lint, Lander Robays, Carlo Heirman, J Reiser, Kris Thielemans, Patrick De Baetselier, Geert Raes, and Karine Breckpot. 2012. “Development of the Nanobody Display Technology to Target Lentiviral Vectors to Antigen-presenting Cells.” Gene Therapy 19 (12): 1133–1140.
Vancouver
1.
Goyvaerts C, De Groeve K, Dingemans J, Van Lint S, Robays L, Heirman C, et al. Development of the nanobody display technology to target lentiviral vectors to antigen-presenting cells. GENE THERAPY. 2012;19(12):1133–40.
IEEE
[1]
C. Goyvaerts et al., “Development of the nanobody display technology to target lentiviral vectors to antigen-presenting cells,” GENE THERAPY, vol. 19, no. 12, pp. 1133–1140, 2012.
@article{6962893,
  abstract     = {Lentiviral vectors (LVs) provide unique opportunities for the development of immunotherapeutic strategies, as they transduce a variety of cells in situ, including antigen-presenting cells (APCs). Engineering LVs to specifically transduce APCs is required to promote their translation towards the clinic. We report on the Nanobody (Nb) display technology to target LVs to dendritic cells (DCs) and macrophages. This innovative approach exploits the budding mechanism of LVs to incorporate an APC-specific Nb and a binding-defective, fusion-competent form of VSV. G in the viral envelope. In addition to production of high titer LVs, we demonstrated selective, Nb-dependent transduction of mouse DCs and macrophages both in vitro and in situ. Moreover, this strategy was translated to a human model in which selective transduction of in vitro generated or lymph node (LN)-derived DCs and macrophages, was demonstrated. In conclusion, the Nb display technology is an attractive approach to generate LVs targeted to specific cell types.},
  author       = {Goyvaerts, Cleo and De Groeve, Kurt and Dingemans, Jozef and Van Lint, Sandra and Robays, Lander and Heirman, Carlo and Reiser, J and Thielemans, Kris and De Baetselier, Patrick and Raes, Geert and Breckpot, Karine},
  issn         = {0969-7128},
  journal      = {GENE THERAPY},
  keywords     = {CANCER-IMMUNOTHERAPY,GENETIC-MODIFICATION,IN-VIVO,DENDRITIC CELLS,VESICULAR STOMATITIS-VIRUS,targeting,lentiviral vector,antigen-presenting cell,Nanobody,T-CELLS,TRANSDUCTION,IMMUNIZATION,IMMUNITY,THERAPY},
  language     = {eng},
  number       = {12},
  pages        = {1133--1140},
  title        = {Development of the nanobody display technology to target lentiviral vectors to antigen-presenting cells},
  url          = {http://dx.doi.org/10.1038/gt.2011.206},
  volume       = {19},
  year         = {2012},
}

Altmetric
View in Altmetric
Web of Science
Times cited: